Press Room

Article / Dec 01, 2008

Family Owned Businesses

Chemistry Today, December 2008

Private companies usually have their shareholders meet every Sunday lunch, shop talk is kept to a minimum so as not to offend the “in-laws” and siblings not involved in the business.
Family owned companies are involved in management and get remunerated by far more than just dividends. The reputation that comes with a company that does well, that is a highly sought-after employer, that leads in innovation, in environmental thinking and international expansion, that does things right - rubs onto the family. For a family to be leading a business that is a role model brings a non-monetary compensation that makes this tight-knit group far richer than any stock market investor could ever be. Can you imagine the pride of a family where the business it owns addresses the capacity needs for the only paediatric HIV protease inhibitor? or the most innovative (avian) flu medicine?

Full version of Family owned businesses article

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025